0001096752--09-302022Q2FALSEMarch 31,
20220.0110,000,000————0.01300,000,00065,251,9891.20.91,250.000010967522021-10-012022-03-3100010967522022-04-30xbrli:shares00010967522022-01-012022-03-31iso4217:USD00010967522021-01-012021-03-3100010967522020-10-012021-03-31iso4217:USDxbrli:shares00010967522022-03-3100010967522021-09-3000010967522020-09-3000010967522021-03-310001096752us-gaap:CommonStockMember2021-09-300001096752us-gaap:TreasuryStockMember2021-09-300001096752us-gaap:AdditionalPaidInCapitalMember2021-09-300001096752us-gaap:RetainedEarningsMember2021-09-300001096752us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001096752us-gaap:RetainedEarningsMember2021-10-012021-12-3100010967522021-10-012021-12-310001096752us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-10-012021-12-310001096752us-gaap:TreasuryStockMember2021-10-012021-12-310001096752us-gaap:AdditionalPaidInCapitalMember2021-10-012021-12-310001096752us-gaap:CommonStockMember2021-12-310001096752us-gaap:TreasuryStockMember2021-12-310001096752us-gaap:AdditionalPaidInCapitalMember2021-12-310001096752us-gaap:RetainedEarningsMember2021-12-310001096752us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100010967522021-12-310001096752us-gaap:RetainedEarningsMember2022-01-012022-03-310001096752us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001096752us-gaap:TreasuryStockMember2022-01-012022-03-310001096752us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001096752us-gaap:CommonStockMember2022-03-310001096752us-gaap:TreasuryStockMember2022-03-310001096752us-gaap:AdditionalPaidInCapitalMember2022-03-310001096752us-gaap:RetainedEarningsMember2022-03-310001096752us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001096752us-gaap:CommonStockMember2020-09-300001096752us-gaap:TreasuryStockMember2020-09-300001096752us-gaap:AdditionalPaidInCapitalMember2020-09-300001096752us-gaap:RetainedEarningsMember2020-09-300001096752us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001096752us-gaap:RetainedEarningsMember2020-10-012020-12-3100010967522020-10-012020-12-310001096752us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-10-012020-12-310001096752us-gaap:TreasuryStockMember2020-10-012020-12-310001096752us-gaap:AdditionalPaidInCapitalMember2020-10-012020-12-310001096752us-gaap:CommonStockMember2020-12-310001096752us-gaap:TreasuryStockMember2020-12-310001096752us-gaap:AdditionalPaidInCapitalMember2020-12-310001096752us-gaap:RetainedEarningsMember2020-12-310001096752us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100010967522020-12-310001096752us-gaap:RetainedEarningsMember2021-01-012021-03-310001096752us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001096752us-gaap:TreasuryStockMember2021-01-012021-03-310001096752us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001096752us-gaap:CommonStockMember2021-03-310001096752us-gaap:TreasuryStockMember2021-03-310001096752us-gaap:AdditionalPaidInCapitalMember2021-03-310001096752us-gaap:RetainedEarningsMember2021-03-310001096752us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-31epc:country0001096752srt:RestatementAdjustmentMember2021-10-012021-12-310001096752epc:BillieMember2021-11-292021-11-2900010967522021-11-292021-11-290001096752epc:BillieMember2021-11-290001096752epc:BillieMember2021-10-012022-03-310001096752us-gaap:SellingGeneralAndAdministrativeExpensesMemberepc:BillieMember2022-01-012022-03-310001096752us-gaap:SellingGeneralAndAdministrativeExpensesMemberepc:BillieMember2021-10-012022-03-310001096752epc:BillieMemberus-gaap:CostOfSalesMember2022-01-012022-03-310001096752epc:BillieMemberus-gaap:CostOfSalesMember2021-10-012022-03-310001096752epc:ITEnablementMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001096752epc:ITEnablementMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310001096752epc:ITEnablementMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-10-012021-03-310001096752us-gaap:InventoryValuationAndObsolescenceMemberus-gaap:CostOfSalesMember2020-10-012021-03-310001096752us-gaap:EmployeeSeveranceMember2021-09-300001096752us-gaap:EmployeeSeveranceMember2021-10-012022-03-310001096752us-gaap:EmployeeSeveranceMember2022-03-310001096752epc:AssetImpairmentandAcceleratedDepreciationMember2021-09-300001096752epc:AssetImpairmentandAcceleratedDepreciationMember2021-10-012022-03-310001096752epc:AssetImpairmentandAcceleratedDepreciationMember2022-03-310001096752us-gaap:OtherRestructuringMember2021-09-300001096752us-gaap:OtherRestructuringMember2021-10-012022-03-310001096752us-gaap:OtherRestructuringMember2022-03-31xbrli:pure0001096752us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001096752us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001096752us-gaap:RestrictedStockUnitsRSUMember2021-10-012022-03-310001096752us-gaap:RestrictedStockUnitsRSUMember2020-10-012021-03-310001096752us-gaap:EmployeeStockOptionMember2021-10-012022-03-310001096752us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001096752us-gaap:RestrictedStockUnitsRSUMember2021-10-012022-03-310001096752us-gaap:EmployeeStockOptionMember2020-10-012021-03-310001096752us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001096752us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001096752epc:WetShaveSegmentMember2021-09-300001096752epc:SunandSkinCareSegmentMember2021-09-300001096752epc:FeminineCareSegmentMember2021-09-300001096752epc:WetShaveSegmentMember2021-10-012022-03-310001096752epc:SunandSkinCareSegmentMember2021-10-012022-03-310001096752epc:FeminineCareSegmentMember2021-10-012022-03-310001096752epc:WetShaveSegmentMember2022-03-310001096752epc:SunandSkinCareSegmentMember2022-03-310001096752epc:FeminineCareSegmentMember2022-03-310001096752us-gaap:TrademarksAndTradeNamesMember2022-03-310001096752us-gaap:TrademarksAndTradeNamesMember2021-09-300001096752us-gaap:TechnologyBasedIntangibleAssetsMember2022-03-310001096752us-gaap:TechnologyBasedIntangibleAssetsMember2021-09-300001096752us-gaap:CustomerRelatedIntangibleAssetsMember2022-03-310001096752us-gaap:CustomerRelatedIntangibleAssetsMember2021-09-300001096752epc:AccountsReceivableSalesAgreementMember2022-01-012022-03-310001096752epc:AccountsReceivableSalesAgreementMember2021-10-012022-03-310001096752epc:AccountsReceivableSalesAgreementMember2021-01-012021-03-310001096752epc:AccountsReceivableSalesAgreementMember2020-10-012021-03-310001096752epc:AccountsReceivableSalesAgreementMember2022-03-310001096752epc:AccountsReceivableSalesAgreementMember2021-09-300001096752epc:SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2022-03-310001096752epc:SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2021-09-300001096752epc:SeniorNotesDue2029Memberus-gaap:SeniorNotesMember2022-03-310001096752epc:SeniorNotesDue2029Memberus-gaap:SeniorNotesMember2021-09-300001096752us-gaap:RevolvingCreditFacilityMember2022-03-310001096752us-gaap:RevolvingCreditFacilityMember2021-09-3000010967522018-01-260001096752us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300001096752us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300001096752us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-09-300001096752us-gaap:AccumulatedTranslationAdjustmentMember2021-10-012022-03-310001096752us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-10-012022-03-310001096752us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-10-012022-03-310001096752us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310001096752us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-03-310001096752us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-03-310001096752us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300001096752us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-300001096752us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-09-300001096752us-gaap:AccumulatedTranslationAdjustmentMember2020-10-012021-03-310001096752us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-10-012021-03-310001096752us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-10-012021-03-310001096752us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310001096752us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-03-310001096752us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-03-310001096752us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NonoperatingIncomeExpenseMember2022-01-012022-03-310001096752us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NonoperatingIncomeExpenseMember2021-01-012021-03-310001096752us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NonoperatingIncomeExpenseMember2021-10-012022-03-310001096752us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NonoperatingIncomeExpenseMember2020-10-012021-03-310001096752us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001096752us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001096752us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-10-012022-03-310001096752us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-10-012021-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-09-30epc:contracts0001096752us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:NonoperatingIncomeExpenseMember2022-01-012022-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:NonoperatingIncomeExpenseMember2021-10-012022-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:NonoperatingIncomeExpenseMember2021-01-012021-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:NonoperatingIncomeExpenseMember2020-10-012021-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-09-300001096752us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-01-012022-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-01-012021-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-10-012022-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2020-10-012021-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NonoperatingIncomeExpenseMemberus-gaap:CashFlowHedgingMember2022-01-012022-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NonoperatingIncomeExpenseMemberus-gaap:CashFlowHedgingMember2021-01-012021-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NonoperatingIncomeExpenseMemberus-gaap:CashFlowHedgingMember2021-10-012022-03-310001096752us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NonoperatingIncomeExpenseMemberus-gaap:CashFlowHedgingMember2020-10-012021-03-310001096752us-gaap:ForeignExchangeContractMember2022-03-310001096752us-gaap:ForeignExchangeContractMember2021-09-300001096752us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001096752us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001096752epc:FixedRateDebtMember2022-03-310001096752epc:FixedRateDebtMember2021-09-300001096752epc:WetShaveSegmentMember2022-01-012022-03-310001096752epc:WetShaveSegmentMember2021-01-012021-03-310001096752epc:WetShaveSegmentMember2020-10-012021-03-310001096752epc:SunandSkinCareSegmentMember2022-01-012022-03-310001096752epc:SunandSkinCareSegmentMember2021-01-012021-03-310001096752epc:SunandSkinCareSegmentMember2020-10-012021-03-310001096752epc:FeminineCareSegmentMember2022-01-012022-03-310001096752epc:FeminineCareSegmentMember2021-01-012021-03-310001096752epc:FeminineCareSegmentMember2020-10-012021-03-310001096752us-gaap:CorporateMember2022-01-012022-03-310001096752us-gaap:CorporateMember2021-01-012021-03-310001096752us-gaap:CorporateMember2021-10-012022-03-310001096752us-gaap:CorporateMember2020-10-012021-03-310001096752us-gaap:CorporateAndOtherMember2022-01-012022-03-310001096752us-gaap:CorporateAndOtherMember2021-01-012021-03-310001096752us-gaap:CorporateAndOtherMember2021-10-012022-03-310001096752us-gaap:CorporateAndOtherMember2020-10-012021-03-310001096752epc:CremoMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310001096752epc:CremoMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-10-012021-03-310001096752epc:CremoMemberus-gaap:CostOfSalesMember2021-10-012022-03-310001096752country:US2022-01-012022-03-310001096752country:US2021-01-012021-03-310001096752country:US2021-10-012022-03-310001096752country:US2020-10-012021-03-310001096752us-gaap:NonUsMember2022-01-012022-03-310001096752us-gaap:NonUsMember2021-01-012021-03-310001096752us-gaap:NonUsMember2021-10-012022-03-310001096752us-gaap:NonUsMember2020-10-012021-03-310001096752epc:RazorsandbladesMember2022-01-012022-03-310001096752epc:RazorsandbladesMember2021-01-012021-03-310001096752epc:RazorsandbladesMember2021-10-012022-03-310001096752epc:RazorsandbladesMember2020-10-012021-03-310001096752epc:TamponsPadsandLinersMember2022-01-012022-03-310001096752epc:TamponsPadsandLinersMember2021-01-012021-03-310001096752epc:TamponsPadsandLinersMember2021-10-012022-03-310001096752epc:TamponsPadsandLinersMember2020-10-012021-03-310001096752epc:SuncareproductsMember2022-01-012022-03-310001096752epc:SuncareproductsMember2021-01-012021-03-310001096752epc:SuncareproductsMember2021-10-012022-03-310001096752epc:SuncareproductsMember2020-10-012021-03-310001096752epc:GroomingProductsMember2022-01-012022-03-310001096752epc:GroomingProductsMember2021-01-012021-03-310001096752epc:GroomingProductsMember2021-10-012022-03-310001096752epc:GroomingProductsMember2020-10-012021-03-310001096752epc:WipesAndOtherSkinCareProductsMember2022-01-012022-03-310001096752epc:WipesAndOtherSkinCareProductsMember2021-01-012021-03-310001096752epc:WipesAndOtherSkinCareProductsMember2021-10-012022-03-310001096752epc:WipesAndOtherSkinCareProductsMember2020-10-012021-03-310001096752epc:ShavinggelsandcreamsMember2022-01-012022-03-310001096752epc:ShavinggelsandcreamsMember2021-01-012021-03-310001096752epc:ShavinggelsandcreamsMember2021-10-012022-03-310001096752epc:ShavinggelsandcreamsMember2020-10-012021-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
FORM 10-Q
_______________________________
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______________ to _______________

Commission File Number: 001-15401
____________________________________________________________________________________________________________
epc-20220331_g1.jpg
EDGEWELL PERSONAL CARE COMPANY
(Exact name of registrant as specified in its charter)
Missouri43-1863181
(State or other jurisdiction of incorporation or organization)(I. R. S. Employer Identification No.)
6 Research Drive(203)944-5500
Shelton,CT06484(Registrant’s telephone number, including area code)
(Address of principal executive offices and zip code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareEPCNew York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐ (Do not check if a smaller reporting company)Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
Common shares, $0.01 par value - 52,802,412 shares as of April 30, 2022.


EDGEWELL PERSONAL CARE COMPANY
INDEX TO FORM 10-Q
PART I.FINANCIAL INFORMATION
Item 1.Financial Statements.
Condensed Consolidated Statements of Earnings and Comprehensive Income for the three and six months ended March 31, 2022 and 2021.
Condensed Consolidated Balance Sheets as of March 31, 2022 and September 30, 2021.
Condensed Consolidated Statements of Cash Flows for the six months ended March 31, 2022 and 2021.
Condensed Consolidated Statements of Changes in Shareholders’ Equity for the three and six months ended March 31, 2022 and 2021.
Notes to Condensed Consolidated Financial Statements.
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Item 3.Quantitative and Qualitative Disclosures About Market Risk.
Item 4.Controls and Procedures.
PART II.OTHER INFORMATION
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds.
Item 6.Exhibits.
SIGNATURE


2


PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.

EDGEWELL PERSONAL CARE COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME
(unaudited, in millions, except per share data)
 Three Months Ended
March 31,		Six Months Ended
March 31,
 2022202120222021
Net sales$547.7 $519.3 $1,011.0 $970.4 
Cost of products sold317.6 277.6 591.0 535.4 
Gross profit230.1 241.7 420.0 435.0 
Selling, general and administrative expense101.3 93.4 198.2 186.5 
Advertising and sales promotion expense69.9 68.4 116.1 109.6 
Research and development expense13.7 14.3 26.5 28.0 
Restructuring charges3.5 2.7 5.7 6.4 
Operating income41.7 62.9 73.5 104.5 
Interest expense associated with debt18.0 17.3 35.3 34.7 
Cost of early retirement of long-term debt— 26.1 — 26.1 
Other income, net(3.4)— (5.1)(1.0)
Earnings before income taxes27.1 19.5 43.3 44.7 
Income tax provision3.9 5.1 8.9 12.6 
Net earnings$23.2 $14.4 $34.4 $32.1 
Earnings per share:
Basic net earnings per share $0.43 $0.26 $0.64 $0.59 
Diluted net earnings per share$0.43 $0.26 $0.63 $0.58 
Statements of Comprehensive Income:
Net earnings$23.2 $14.4 $34.4 $32.1 
Other comprehensive (loss) income, net of tax
Foreign currency translation adjustments(9.0)(19.8)(15.9)13.9 
Pension and postretirement activity, net of tax of $0.2, $0.8, $0.3, and $0.0
0.1 1.4 0.1 (0.6)
Deferred gain on hedging activity, net of tax of $0.5, $2.4, $0.6, and $1.6
1.0 5.1 1.4 3.3 
Total other comprehensive (loss) income, net of tax(7.9)(13.3)(14.4)16.6 
Total comprehensive income$15.3 $1.1 $20.0 $48.7 

See accompanying Notes to Condensed Consolidated Financial Statements.
3

EDGEWELL PERSONAL CARE COMPANY
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in millions, except share data)
 
March 31,
2022		September 30,
2021
Assets
Current assets 
Cash and cash equivalents$188.1 $479.2 
Trade receivables, less allowance for doubtful accounts of $7.8 and $6.9
183.8 150.7 
Inventories429.1 345.7 
Other current assets167.7 160.1 
Total current assets968.7 1,135.7 
Property, plant and equipment, net355.4 362.6 
Goodwill1,340.6 1,162.8 
Other intangible assets, net1,024.2 906.4 
Other assets104.4 107.1 
Total assets$3,793.3 $3,674.6 
Liabilities and Shareholders’ Equity
Current liabilities
Notes payable$25.8 $26.5 
Accounts payable224.7 209.5 
Other current liabilities293.7 300.8 
Total current liabilities544.2 536.8 
Long-term debt1,414.3 1,234.2 
Deferred income tax liabilities139.1 129.0 
Other liabilities180.2 190.3 
Total liabilities2,277.8 2,090.3 
Shareholders’ equity
Preferred shares, $0.01 par value, 10,000,000 authorized; none issued or outstanding
— — 
Common shares, $0.01 par value, 300,000,000 authorized; 65,251,989 issued; 52,895,050 and 54,369,714 outstanding
0.7 0.7 
Additional paid-in capital1,597.2 1,631.1 
Retained earnings883.5 865.7 
Common shares in treasury at cost, 12,356,939 and 10,882,275
(814.6)(776.3)
Accumulated other comprehensive loss(151.3)(136.9)
Total shareholders’ equity1,515.5 1,584.3 
Total liabilities and shareholders’ equity$3,793.3 $3,674.6 

See accompanying Notes to Condensed Consolidated Financial Statements.


4

EDGEWELL PERSONAL CARE COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in millions)
 Six Months Ended
March 31,
 20222021
Cash Flow from Operating Activities  
Net earnings$34.4 $32.1 
Depreciation and amortization44.6 44.4 
Share-based compensation expense12.2 12.0 
Loss on sale of assets0.4 0.4 
Deferred compensation payments(7.1)(8.8)
Deferred income taxes(10.5)(0.8)
Cost of early retirement of long-term debt— 26.1 
Other, net(0.9)(1.6)
Changes in operating assets and liabilities(113.0)(122.6)
Net cash used by operating activities$(39.9)$(18.8)
Cash Flow from Investing Activities
Capital expenditures(25.0)(22.2)
Acquisition of Billie, net of cash acquired(309.4)— 
Proceeds from sale of Infant and Pet Care business5.0 7.5 
Acquisition of Cremo— (0.3)
Collection of deferred purchase price on accounts receivable sold4.7 2.2 
Other, net(1.0)(0.8)
Net cash used by investing activities$(325.7)$(13.6)
Cash Flow from Financing Activities
Cash proceeds from the issuance of Senior Notes due 2029— 500.0 
Cash payments on Senior Notes due 2022— (500.0)
Cash proceeds from debt with original maturities greater than 90 days399.0 — 
Cash payments on debt with original maturities greater than 90 days(220.0)— 
Net increase in debt with original maturities of 90 days or less0.7 0.7 
Debt issuance costs for Senior Notes due 2029— (5.9)
Cost of early retirement of long-term debt— (26.5)
Dividends to common shareholders(16.7)(8.4)
Repurchase of shares(75.4)(9.2)
Net financing (outflow) inflow from the Accounts Receivable Facility(0.2)0.7 
Employee shares withheld for taxes(9.7)(3.0)
Other, net0.6 (0.5)
Net cash from (used by) financing activities$78.3 $(52.1)
Effect of exchange rate changes on cash(3.8)1.9 
Net decrease in cash and cash equivalents(291.1)(82.6)
Cash and cash equivalents, beginning of period479.2 364.7 
Cash and cash equivalents, end of period$188.1 $282.1 

See accompanying Notes to Condensed Consolidated Financial Statements.
5

EDGEWELL PERSONAL CARE COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
(unaudited, in millions)

Common SharesTreasury Shares
NumberPar ValueNumberAmountAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive LossTotal Shareholders’ Equity
Balance at September 30, 202165.2 $0.7 (10.9)$(776.3)$1,631.1 $865.7 $(136.9)$1,584.3 
Net earnings— — — — — 11.2 — 11.2 
Foreign currency translation adjustments— — — — — — (6.9)(6.9)
Deferred gain on hedging activity— — — — — — 0.4 0.4 
Dividends declared to common shareholders— — — — — (8.4)— (8.4)
Repurchase of shares— — (0.5)(24.5)— — — (24.5)
Activity under share plans— — 0.3 33.6 (37.4)— — (3.8)
Balance at December 31, 202165.2 $0.7 (11.1)$(767.2)$1,593.7 $868.5 $(143.4)$1,552.3 
Net earnings— — — — — 23.2 — 23.2 
Foreign currency translation adjustments— — — — — — (9.0)(9.0)
Pension and postretirement activity— — — — — — 0.1 0.1 
Deferred gain on hedging activity— — — — — — 1.0 1.0 
Dividends declared to common shareholders— — — — — (8.2)— (8.2)
Repurchase of shares— — (1.4)(50.9)— — — (50.9)
Activity under share plans— — 0.1 3.5 3.5 — — 7.0 
Balance at March 31, 202265.2 $0.7 (12.4)$(814.6)$1,597.2 $883.5 $(151.3)$1,515.5 





6

Common SharesTreasury Shares
NumberPar ValueNumberAmountAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive LossTotal Shareholders’ Equity
Balance at September 30, 202065.2 $0.7 (10.9)$(790.4)$1,631.8 $782.4 $(191.6)$1,432.9 
Net earnings— — — — — 17.7 — 17.7 
Foreign currency translation adjustments— — — — — — 33.7 33.7 
Pension and postretirement activity— — — — — — (2.0)(2.0)
Deferred loss on hedging activity— — — — — — (1.8)(1.8)
Dividends declared to common shareholders— — — — — (8.5)— (8.5)
Repurchase of shares— — (0.3)(9.2)— — — (9.2)
Activity under share plans— — 0.2 15.4 (13.0)— — 2.4 
Balance at December 31, 202065.2 $0.7 (11.0)$(784.2)$1,618.8 $791.6 $(161.7)$1,465.2 
Net earnings— — — — — 14.4 — 14.4 
Foreign currency translation adjustments— — — — — — (19.8)(19.8)
Pension and postretirement activity— — — — — — 1.4 1.4 
Deferred gain on hedging activity— — — — — — 5.1 5.1 
Dividends declared to common shareholders— — — — — (8.3)— (8.3)
Activity under share plans— — 0.1 2.9 3.2 — — 6.1 
Balance at March 31, 202165.2 $0.7 (10.9)$(781.3)$1,622.0 $797.7 $(175.0)$1,464.1 

See accompanying Notes to Condensed Consolidated Financial Statements.


7

EDGEWELL PERSONAL CARE COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, in millions, except per share data)

Note 1 - Background and Basis of Presentation
Background
Edgewell Personal Care Company and its subsidiaries (collectively, “Edgewell” or the “Company”) is one of the world’s largest manufacturers and marketers of personal care products in the wet shave, sun and skin care, and feminine care categories. Edgewell operates in more than 20 countries and has a global footprint in more than 50 countries.
The Company conducts its business in the following three segments:
•Wet Shave consists of products sold under the Schick®, Wilkinson Sword®, Edge, Skintimate®, Billie®, Shave Guard and Personna® brands, as well as non-branded products. The Company’s wet shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams.
•Sun and Skin Care consists of Banana Boat® and Hawaiian Tropic® sun care products, Jack Black®, Bulldog® and Cremo® men’s grooming products, and Wet Ones® products.
•Feminine Care includes tampons, pads, and liners sold under the Playtex Gentle Glide® and Sport®, Stayfree®, Carefree®, and o.b.® brands.

Basis of Presentation
The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its controlled subsidiaries and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) under the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). The preparation of the unaudited Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ materially from those estimates. All intercompany balances and transactions have been eliminated in consolidation and, in the opinion of management, all normal recurring adjustments considered necessary for a fair statement have been included in the interim results reported. The fiscal year-end balance sheet data was derived from audited consolidated financial statements, but do not include all of the annual disclosures required by GAAP; accordingly, these unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited annual consolidated financial statements included in its Annual Report on Form 10-K filed with the SEC on November 19, 2021.
Acquisition of Billie, Inc. On November 29, 2021, the Company completed the acquisition of Billie, Inc. (“Billie”) (the “Acquisition”), a leading U.S. based consumer brand company that offers a broad portfolio of personal care products for women. The results of Billie for the post-acquisition period are included within the Company’s results since the acquisition date. For more information on the Acquisition, see Note 2 of Notes to Condensed Consolidated Financial Statements.
Recently Adopted Accounting Pronouncements.
In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update 2019-12, which eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period when interim loss exceeds anticipated loss for the year, and the recognition of deferred tax liabilities for outside basis differences related to changes in ownership of equity method investments and foreign subsidiaries. The guidance also simplifies aspects of accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard as of October 1, 2021. There was no cumulative effect adjustment recorded to retained earnings as the amount was not material, and the effects of this standard on our financial position, results of operations and cash flows were not material.
Statement of Cash Flows Presentation
The net presentation of borrowings and repayments under the Company's U.S revolving credit facility in the Condensed Consolidated Statement of Cash Flows for the three months ended December 31, 2021 has been corrected in order to reflect borrowings and repayments on a gross basis, resulting in $93.0 of repayments presented gross that were previously netted against borrowings. Net cash from financing activities reported in the Condensed Consolidated Statement of Cash Flows for the three months ended December 31, 2021 was not impacted and the Company has concluded that this correction is not material to its financial statements.
8

Note 2 - Business Combinations
Billie Inc.
On November 29, 2021 (the “Acquisition Date”), the Company completed the Acquisition for cash consideration of $309.4, net of cash acquired. As a result of the Acquisition, Billie became a wholly owned subsidiary of the Company. The Company accounted for the Acquisition utilizing the acquisition method of accounting, which requires assets and liabilities to be recognized based on estimates of their acquisition date fair values. The determination of the values of the acquired assets and assumed liabilities, including goodwill, other intangible assets and deferred taxes, requires significant judgement. The purchase price allocation remains preliminary, as certain information is not yet available. This includes, but is not limited to, the finalization of the fair value of certain assets and liabilities, including the completion of intangible asset valuations. Additionally, tax returns and analyses required to calculate the underlying tax basis of Billie’s assets, liabilities and net operating losses have not been finalized. We expect to complete the purchase price allocation during the 12-month period following the Acquisition Date, during which time the value of the assets and liabilities may be revised as appropriate.
The Company used variations of the income approach in determining the fair value of intangible assets acquired in the Acquisition. Specifically, we utilized the multi-period excess earnings method to determine the fair value of the definite lived customer relationships acquired and the relief from royalty method to determine the fair value of the definite lived trade name acquired. Our determination of the fair value of the intangible assets acquired involved the use of significant estimates and assumptions related to revenue growth rates, discount rates, customer attrition rates, and royalty rates. Edgewell believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use.
The following table provides the preliminary allocation of the purchase price related to the Acquisition based upon the fair value of assets and liabilities assumed:
Current assets$17.0 
Goodwill181.5
Intangible assets136.0
Other assets, including property, plant and equipment, net3.2
Current liabilities(6.9)
Deferred tax liabilities(21.4)
$309.4 
The acquired goodwill represented the value of expansion into new markets and channels of trade and is not deductible for tax purposes. The intangible assets acquired consisted primarily of the Billie trade name and customer relationships with a weighted average useful life of 19 years. All assets are included in the Company’s Wet Shave segment.
Billie contributed Net sales and a Loss before income taxes totaling $40.9 and $4.4, respectively, for the post-acquisition period ending March 31, 2022 in the Condensed Consolidated Statements of Earnings and Comprehensive Income. The Loss before income taxes was driven primarily by amortization expense of acquired intangible assets. Acquisition and integration costs related to Billie totaling $0.6 and $6.3 were included in Selling, general and administrative expense (“SG&A”) and acquisition costs of $0.5 and $0.8 were included in Cost of products sold in the Condensed Consolidated Statements of Earnings and Comprehensive Income for the three and six months ended March 31, 2022, respectively.
The following summarizes the company's unaudited pro forma consolidated results of operations for the three and six months ended March 31, 2022 and March 31, 2021, as though the Acquisition occurred on October 1, 2020:
Three Months Ended
March 31,		Six Months Ended
March 31,
2022202120222021
Pro forma net sales$547.7 $536.2 $1,021.0 $1,003.5 
Pro forma net earnings23.98.238.718.4
9

The unaudited pro forma consolidated results of operations were adjusted by pre-tax amortization expense of $1.3 for the six months ended March 31, 2022, compared to $2.1 and $4.3 for the three and six months ended March 31, 2021, respectively. Additionally, pro forma earnings for the three and six months ended March 31, 2022 exclude $1.1 and $7.1 of pre-tax acquisition costs, respectively, which were included in the pro forma earnings for the three and six months ended March 31, 2021, respectively. The pro forma earnings were also adjusted to reflect the capital structure as of the Acquisition Date, and all pro forma adjustments have been included with related tax effects. The unaudited pro forma consolidated results of operations is not necessarily indicative of the results obtained had the Acquisition occurred on October 1, 2020, or of those results that may be obtained in the future. Amounts do not reflect any anticipated cost savings or cross-selling opportunities expected to result from the Acquisition.

Note 3 - Restructuring Charges
Operating Model Redesign
In fiscal 2022, the Company expects to take specific actions to strengthen its operating model, simplify the organization and improve manufacturing and supply chain efficiency and productivity. As a result of these actions, we expect to incur one-time charges of approximately $15 in fiscal 2022. The Company incurred the following restructuring charges for the three and six months ended March 31, 2022:
Three Months Ended
 March 31, 2022		Six Months Ended
March 31, 2022
Severance and related benefit costs$1.7 $3.0 
Asset write-off and accelerated depreciation0.1 0.1 
Consulting, project implementation and management, and other exit costs1.9 2.8 
Total restructuring$3.7 $5.9 
Pre-tax SG&A of $0.2 for the three and six months ended March 31, 2022, associated with certain information technology enablement expenses and compensation expenses for restructuring programs were included in Consulting, project implementation and management, and other exit costs.

Project Fuel
Project Fuel was an enterprise-wide transformational initiative launched in fiscal 2018 to improve operational performance and reshape the business’ cost structure. Project Fuel was completed on September 30, 2021.
The Company incurred the following restructuring charges for the three and six months ended March 31, 2021:
Three Months Ended
March 31, 2021		Six Months Ended
March 31, 2021
Severance and related benefit costs$2.0 4.3 
Asset write-off and accelerated depreciation0.1 0.2 
Consulting, project implementation and management, and other exit costs3.4 5.4 
Total restructuring$5.5 $9.9 
Pre-tax SG&A of $2.8 and $3.4 for the three and six months ended March 31, 2021, respectively, associated with certain information technology enablement expenses and compensation expenses related to Project Fuel were included in Consulting, project implementation and management, and other exit costs. Pre-tax Cost of products sold of $0.1 for the six months ended March 31, 2021 related to inventory write-offs associated with Project Fuel, were included in Asset impairment and accelerated depreciation.
10

The following table summarizes the restructuring activities and related accrual for the six months ended March 31, 2022:
Utilized
October 1, 2021Charge to
Income		CashNon-CashMarch 31,
2022
Severance and related benefit costs$1.9 $3.0 $(3.0)$— $1.9 
Asset write-off and accelerated depreciation— 0.1 — (0.1)— 
Consulting, project implementation and management, and other exit costs3.6 2.8 (5.5)— 0.9 
Total restructuring$5.5 $5.9 $(8.5)$(0.1)$2.8 

Note 4 - Income Taxes
For the three and six months ended March 31, 2022, the Company had income tax expense of $3.9 and $8.9, respectively, on Earnings before income taxes of $27.1 and $43.3, respectively. The effective tax rate for the three and six months ended March 31, 2022 was 14.4% and 20.5%, respectively. The difference between the federal statutory rate and the effective rate is primarily due to a favorable mix of earnings in low tax jurisdictions and the favorable impact of a change in the Company’s prior estimates.
For the three and six months ended March 31, 2021, the Company had income tax expense of $5.1 and $12.6, respectively, on Earnings before income taxes of $19.5 and $44.7, respectively. The effective tax rate for the three and six months ended March 31, 2021 was 26.6% and 28.4%, respectively. The difference between the federal statutory rate and the effective rate for the three and six months ended March 31, 2021 is primarily due to the unfavorable mix of earnings in higher tax rate jurisdictions as well as unfavorable global intangible low-tax income and Internal Revenue Service Code Section 162(m) permanent adjustments.

Note 5 - Earnings per Share
Basic earnings per share is based on the weighted-average number of common shares outstanding during the period. Diluted earnings per share is based on the number of shares used for the basic earnings per share calculation, adjusted for the dilutive effect of share options and restricted share equivalent (“RSE”) and performance restricted share equivalent (“PRSE”) awards.
The following is the reconciliation between the number of weighted-average shares used in the basic and diluted earnings per share calculation:    
Three Months Ended
March 31,		Six Months Ended
March 31,
 2022202120222021
Basic weighted-average shares outstanding53.6 54.3 54.0 54.4 
Effect of dilutive securities:
RSE and PRSE awards0.7 0.6 0.6 0.5 
Total dilutive securities0.7 0.6 0.6 0.5 
Diluted weighted-average shares outstanding54.3 54.9 54.6 54.9 
For the three and six months ended March 31, 2022, the calculation of diluted weighted-average shares outstanding excludes 1.2 of share options. For the three and six months ended March 31, 2022 the calculation excludes 0.1 and 0.4, respectively, of RSE and PRSE awards because the effect of including these awards was anti-dilutive. For the three and six months ended March 31, 2021, the calculation of diluted weighted-average shares outstanding excludes 0.9 of share options because the effect of including these awards was anti-dilutive.
 
11

Note 6 - Goodwill and Intangible Assets
The following table sets forth goodwill by segment:
Wet
Shave		Sun and Skin
Care		Feminine
Care		Total
Gross balance at October 1, 2021$967.5 $357.6 $208.7 $1,533.8 
Accumulated goodwill impairment(369.0)(2.0)— (371.0)
Net balance at October 1, 2021$598.5 $355.6 $208.7 $1,162.8 
Changes in the six-month period ended March 31, 2022
Billie acquisition181.5 — — 181.5 
Cumulative translation adjustment(3.9)(0.5)0.7 (3.7)
Gross balance at March 31, 2022$1,145.1 $357.1 $209.4 $1,711.6 
Accumulated goodwill impairment(369.0)(2.0)— (371.0)
Net balance at March 31, 2022$776.1 $355.1 $209.4 $1,340.6 
The following table sets forth intangible assets by class:
March 31, 2022September 30, 2021
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Accumulated
Amortization		Net
Indefinite lived
Trade names and brands$596.9 $— $596.9 $600.8 $— $600.8 
Amortizable
Trade names and brands$339.8 $64.8 $275.0 $256.2 $57.7 $198.5 
Technology and patents78.7 75.7 3.0 79.1 75.8 3.3 
Customer related and other272.6 123.3 149.3 221.2 117.4 103.8 
Total amortizable intangible assets$691.1 $263.8 $427.3 $556.5 $250.9 $305.6 
Amortization expense was $7.9 and $14.0 for the three and six months ended March 31, 2022, respectively, and $5.6 and $11.1 for the three and six months ended March 31, 2021, respectively. Estimated amortization expense for amortizable intangible assets for the remainder of fiscal 2022 and for fiscal 2023, 2024, 2025, 2026 and 2027 is $15.5, $30.9, $30.8, $30.8, $30.6 and $30.5, respectively, and $258.2 thereafter.
Goodwill and intangible assets deemed to have an indefinite life are not amortized but are instead reviewed annually for impairment of value or when indicators of a potential impairment are present. The Company’s annual impairment testing date is July 1. An interim impairment analysis may indicate that carrying amounts of goodwill and other intangible assets require adjustment or that remaining useful lives should be revised. The Company determined there was no triggering event requiring an interim impairment analysis during the six months ended March 31, 2022.
12

Note 7 - Supplemental Balance Sheet Information
March 31,
2022		September 30,
2021
Inventories  
Raw materials and supplies$67.2 $61.3 
Work in process91.3 83.4 
Finished products270.6 201.0 
Total inventories$429.1 $345.7 
Other Current Assets 
Miscellaneous receivables$37.4 $30.3 
Inventory returns receivable1.2 0.9 
Prepaid expenses77.5 67.3 
Value added tax collectible from customers19.6 19.6 
Income taxes receivable22.9 29.1 
Other9.1 12.9 
Total other current assets$167.7 $160.1 
Property, Plant and Equipment  
Land$18.8 $19.2 
Buildings143.7 144.5 
Machinery and equipment1,050.8 1,049.0 
Capitalized software costs57.3 57.0 
Construction in progress55.0 44.0 
Total gross property, plant and equipment1,325.6 1,313.7 
Accumulated depreciation and amortization(970.2)(951.1)
Total property, plant and equipment, net$355.4 $362.6 
Other Current Liabilities  
Accrued advertising, sales promotion and allowances$47.0 $33.8 
Accrued trade allowances31.6 34.0 
Accrued salaries, vacations and incentive compensation35.1 66.4 
Income taxes payable10.4 9.8 
Returns reserve48.9 52.7 
Restructuring reserve2.8 5.5 
Value added tax payable7.7 4.6 
Deferred compensation4.6 5.9 
Short term lease obligation11.2 11.0 
Customer advance payments2.1 0.6 
Dividends payable8.0 8.2 
Other84.3 68.3 
Total other current liabilities$293.7 $300.8 
Other Liabilities  
Pensions and other retirement benefits$54.8 $55.4 
Deferred compensation17.9 22.7 
Long term lease obligation44.4 46.9 
Other non-current liabilities63.1 65.3 
Total other liabilities$180.2 $190.3 

13

Note 8 - Leases
The Company leases certain offices and manufacturing facilities, warehouses, employee vehicles and certain manufacturing related equipment and determines if an arrangement is or contains a lease at inception. Leases may include options to extend or terminate the lease, and those options are recorded on the Condensed Consolidated Balance Sheet when it is reasonably certain that the Company will exercise one of those options. All recorded leases are classified as operating leases, and lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheet.
A summary of the Company's lease information is as follows:
March 31,
2022		September 30,
2021
AssetsClassification
Right of use assetsOther assets$55.2 $57.7 
Liabilities
Current lease liabilitiesOther current liabilities$11.2 $11.0 
Long-term lease liabilitiesOther liabilities44.4 46.9 
Total lease liabilities$55.6 $57.9 
Other information
Weighted-average remaining lease term (years)1010
Weighted-average incremental borrowing rate6.4 %6.3 %

Three Months Ended
March 31,		Six Months Ended
March 31,
2022202120222021
Statement of Earnings
Lease cost (1)
$3.3 $3.5 $6.8 $7.4 
Other information
Leased assets obtained in exchange for new lease liabilities2.4 13.8 2.9 17.7 
Cash paid for amounts included in the measurement of lease liabilities$3.3 $3.4 $6.9 $7.4 
(1)Lease expense is included in Cost of products sold or SG&A expense based on the nature of the lease. Short-term lease expense is excluded from this amount and is not material.

The Company's future lease payments, including reasonably assured renewal options under lease agreements, are as follows:
Lease liability repaymentsMarch 31, 2022
Remainder of fiscal 2022$6.5 
202311.4 
20249.3 
20258.4 
20267.0 
2027 and thereafter37.8 
Total future minimum lease commitments80.4 
Less: Imputed interest(24.8)
Present value of lease liabilities$55.6 

14


Note 9 - Accounts Receivable Facility
The Company participates in an uncommitted master accounts receivable purchase agreement dated September 15, 2017 by and between the Company and MUFG Bank, Ltd, formerly known as The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as the purchaser (the “Accounts Receivable Facility”). Transfers under the Accounts Receivable Facility are accounted for as sales of receivables, resulting in the receivables being de-recognized from the Consolidated Balance Sheet. The purchaser assumes the credit risk at the time of sale and has the right at any time to assign, transfer, or participate any of its rights under the purchased receivables to another bank or financial institution. The purchase and sale of receivables under the Accounts Receivable Facility is intended to be an absolute and irrevocable transfer without recourse by the purchaser to the Company for the creditworthiness of any obligor. The Company continues to have collection and servicing responsibilities for the receivables sold and receives separate compensation for their servicing. The compensation received is considered acceptable servicing compensation and, as such, the Company does not recognize a servicing asset or liability.
On February 7, 2022, the Company entered into the Sixth Amendment to Master Accounts Receivable Purchase Agreement between Edgewell Personal Care, LLC and MUFG Bank, LTD., formerly known as The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, which increased the maximum receivables sold amount under the Accounts Receivable Facility to $180.0 from $150.0 and amended the pricing index used to determine the purchase price for subject receivables from LIBOR to the Bloomberg Short Term Bank Yield Index (“BSBY”). The applicable margin that is added to the BSBY pricing index specific for each obligor was unchanged. Except as noted above, all other terms, conditions, obligations, covenants or agreements contained in the Accounts Receivable Facility are unmodified in all respects and continue in full force and effect.
As of March 31, 2022, the discount rate used to determine the purchase price for the subject receivables shall be based upon BSBY plus a margin applicable to the specified obligor.
Accounts receivables sold were $282.0 and $437.2 for the three and six months ended March 31, 2022, respectively, and $201.9 and $340.3 for the three and six months ended March 31, 2021, respectively. The trade receivables sold that remained outstanding as of March 31, 2022 and September 30, 2021 were $134.5 and $91.1, respectively. The net proceeds received were included in both Cash provided by operating activities and Cash provided by investing activities on the Condensed Consolidated Statements of Cash Flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of receivables in Other income, net in the Condensed Consolidated Statements of Earnings and Comprehensive Income. The loss on sale of trade receivables was $0.3 and $0.5 for the three and six months ended March 31, 2022, respectively, and the loss on sale of trade receivables was $0.2 and $0.4 for the three and six months ended March 31, 2021, respectively.

Note 10 - Debt
The detail of long-term debt was as follows:
March 31,
2022		September 30,
2021
Senior notes, fixed interest rate of 5.500%, due 2028$750.0 $750.0 
Senior notes, fixed interest rate of 4.125%, due 2029500.0 500.0 
U.S. revolving credit facility due 2025179.0 — 
Total long-term debt, including current maturities1,429.0 1,250.0 
Less unamortized debt issuance costs and discount (1)
14.7 15.8 
Total long-term debt$1,414.3 $1,234.2 
(1)At March 31, 2022, the balance for the Senior Notes due 2028 and the Senior Notes due 2029 are reflected net of debt issuance costs of $9.1 and $5.6, respectively. At September 30, 2021, the balance for the Senior Notes due 2028 and the Senior Notes due 2029 are reflected net of debt issuance costs of $9.8 and $6.0, respectively.
The Company had outstanding variable-rate international borrowings, recorded in Notes payable, of $25.8 and $26.5 as of March 31, 2022 and September 30, 2021, respectively.

15

Note 11 - Retirement Plans
The Company has several defined benefit pension plans covering employees in the U.S. and certain employees in other countries, which are included in the information presented below. The plans provide retirement benefits based on years of service and compensation. The Company also sponsors or participates in several other non-U.S. pension and postretirement arrangements, including various retirement and termination benefit plans, some of which are required by local law or coordinated with government-sponsored plans, which are not significant in the aggregate and, therefore, are not included in the information presented below.
The Company’s net periodic pension and postretirement costs for these plans were as follows:
Three Months Ended
March 31,		Six Months Ended
March 31,
 2022202120222021
Service cost$1.0 $1.1 $2.0 $2.2 
Interest cost2.6 2.4 5.2 4.9 
Expected return on plan assets(5.3)(5.6)(10.6)(11.2)
Recognized net actuarial loss1.6 2.3 3.1 4.6 
Net periodic cost$(0.1)$0.2 $(0.3)$0.5 
The service cost component of the net periodic cost associated with the Company’s retirement plans is recorded to Cost of products sold and SG&A on the Condensed Consolidated Statement of Earnings and Comprehensive Income. The remaining net periodic cost is recorded to Other income, net on the Condensed Consolidated Statement of Earnings and Comprehensive Income.

Note 12 - Shareholders’ Equity
Share Repurchases
In January 2018, the Company’s Board of Directors (the “Board”) authorized the repurchase of up to 10.0 shares of the Company’s common stock, replacing the previous share repurchase authorization from May 2015. The Company repurchased 1.9 shares of its common stock for $75.4 during the six months ended March 31, 2022 and has 7.8 shares of its common stock available for repurchase in the future under the Board’s authorization. Any future share repurchases may be made in the open market, privately negotiated transactions, or otherwise, and in such amounts and at such times as the Company deems appropriate based upon prevailing market conditions, business needs, and other factors.
Dividends
On February 4, 2022, the Board declared a quarterly cash dividend of $0.15 per common share for the first fiscal quarter. The dividend was paid on April 5, 2022 to stockholders of record as of the close of business on March 8, 2022.
Dividends declared during the six months ended March 31, 2022 totaled $16.6. Payments made for dividends during the six months ended March 31, 2022 totaled $16.7.
On May 6, 2022, the Board declared a quarterly cash dividend of $0.15 per common share for the second fiscal quarter. The dividend is payable July 7, 2022 to stockholders of record as of the close of business on June 2, 2022.

Note 13 - Accumulated Other Comprehensive Loss
The following table presents the changes in accumulated other comprehensive loss (“AOCI”), net of tax, by component:
Foreign
Currency
Translation
Adjustments		Pension and
Post-retirement
Activity		Hedging
Activity		Total
Balance at October 1, 2021$(41.8)$(97.3)$2.2 $(136.9)
OCI before reclassifications (1)
(15.9)(2.2)3.3 (14.8)
Reclassifications to earnings— 2.3 (1.9)0.4 
Balance at March 31, 2022$(57.7)$(97.2)$3.6 $(151.3)
16

Foreign
Currency
Translation
Adjustments		Pension and
Post-retirement
Activity		Hedging
Activity		Total
Balance at October 1, 2020$(47.4)$(142.1)$(2.1)$(191.6)
OCI before reclassifications (1)
13.9 (3.9)1.1 11.1 
Reclassifications to earnings— 3.3 2.2 5.5 
Balance at March 31, 2021$(33.5)$(142.7)$1.2 $(175.0)
(1)OCI is defined as other comprehensive income (loss).
The following table presents the reclassifications out of AOCI:
Three Months Ended
March 31,		Six Months Ended
March 31,		Affected Line Item in the
Condensed Consolidated
Statements of Earnings
Details of AOCI Components2022202120222021
Gain / (Loss) on cash flow hedges
Foreign exchange contracts$1.6 $(1.8)$2.9 $(3.2)Other income, net
0.5 (0.6)1.0 (1.0)Income tax provision
1.1 (1.2)$1.9 $(2.2)
Amortization of defined benefit pension and postretirement items
Actuarial losses$(1.6)$(2.3)$(3.1)$(4.6)(1)
(0.4)(0.7)(0.8)(1.3)Income tax provision
(1.2)(1.6)(2.3)$(3.3)
Total reclassifications for the period$(0.1)$(2.8)$(0.4)$(5.5)
(1)These AOCI components are included in the computation of net periodic cost. See Note 11 of Notes to Condensed Consolidated Financial Statements.

Note 14 - Financial Instruments and Risk Management
In the course of ordinary business, the Company enters into contractual arrangements (also referred to as derivatives) to reduce its exposure to foreign currency. The Company has master netting agreements with all of its counterparties that allow for the settlement of contracts in an asset position with contracts in a liability position in the event of default. The Company manages counterparty risk through the utilization of investment grade commercial banks, diversification of counterparties, and its counterparty netting arrangements. The section below outlines the types of derivatives in place at March 31, 2022 and September 30, 2021, as well as the Company’s objectives and strategies for holding derivative instruments.
Foreign Currency Risk
A significant share of the Company’s sales is tied to currencies other than the U.S. dollar, the Company’s reporting currency. As such, a weakening of currencies relative to the U.S. dollar can have a negative impact on reported earnings. Conversely, strengthening of currencies relative to the U.S. dollar can improve reported results. The primary currencies to which the Company is exposed include the euro, the Japanese yen, the British pound, the Canadian dollar, and the Australian dollar.
Additionally, the Company’s foreign subsidiaries enter into internal and external transactions that create non-functional currency balance sheet positions at the foreign subsidiary level. These exposures are generally the result of intercompany purchases, intercompany loans and, to a lesser extent, external purchases, and are revalued in the foreign subsidiary’s local currency at the end of each month. Changes in the value of the non-functional currency balance sheet positions in relation to the foreign subsidiary’s local currency results in an exchange gain or loss recorded in Other income, net. The primary currency to which the Company’s foreign subsidiaries are exposed is the U.S. dollar.
Cash Flow Hedges
At March 31, 2022, the Company maintained a cash flow hedging program related to foreign currency risk. These derivative instruments have a high correlation to the underlying exposure being hedged and have been deemed highly effective by the Company for accounting purposes in offsetting the associated risk.
17

The Company has forward currency contracts to hedge cash flow uncertainty associated with currency fluctuations. These transactions are accounted for as cash flow hedges. The Company had unrealized pre-tax gains of $5.3 and $3.3 at March 31, 2022 and September 30, 2021, respectively, on these forward currency contracts, which are accounted for as cash flow hedges and included in AOCI. Assuming foreign exchange rates versus the U.S. dollar remain at March 31, 2022 levels over the next 12 months, the majority of the pre-tax gain included in AOCI at March 31, 2022 is expected to be included in Other income, net. Contract maturities for these hedges extend into fiscal 2023. At March 31, 2022, there were 64 open foreign currency contracts with a total notional value of $127.2.
Derivatives not Designated as Hedges
The Company has foreign currency derivative contracts, which are not designated as cash flow hedges for accounting purposes, to hedge balance sheet exposures. Any gains or losses on these contracts are expected to be offset by exchange gains or losses on the underlying exposures and, thus, are not subject to significant market risk. The change in the estimated fair value of the foreign currency contracts for the three and six months ended March 31, 2022 resulted in gains of $0.6 and $1.7, respectively, compared to $3.0 and $1.9 for the three and six months ended March 31, 2021, respectively, and was recorded in Other income, net in the Condensed Consolidated Statements of Earnings and Comprehensive Income. At March 31, 2022, there were five open foreign currency derivative contracts not designated as cash flow hedges with a total notional value of $39.0.
The following table provides estimated fair values of derivative instruments:
Fair Value of Assets (1)
March 31,
2022		September 30,
2021
Derivatives designated as cash flow hedging relationships:
Foreign currency contracts$5.3 $3.3 
Derivatives not designated as cash flow hedging relationships:
Foreign currency contracts$1.7 $0.5 
(1)All derivative assets are presented in Other current assets or Other assets.
The following table provides the amounts of gains and losses on derivative instruments:
Three Months Ended
March 31,		Six Months Ended
March 31,
2022202120222021
Derivatives designated as cash flow hedging relationships:
Foreign currency contracts 
Gain recognized in OCI (1)
$3.1 $5.7 $4.9 $1.7 
Gain (loss) reclassified from AOCI into income (1) (2)
1.6 (1.8)2.9 (3.2)
Derivatives not designated as cash flow hedging relationships:
Foreign currency contracts
Gain recognized in income (2)
$0.6 $3.0 $1.7 $1.9 
(1)Each of these derivative instruments had a high correlation to the underlying exposure being hedged for the periods indicated and have been deemed highly effective by the Company in offsetting associated risk.
(2)Gain (loss) was recorded in Other income, net.
The following table provides financial assets and liabilities for balance sheet offsetting:
At March 31, 2022At September 30, 2021
Assets (1)
Liabilities (2)
Assets (1)
Liabilities (2)
Foreign currency contracts
Gross amounts of recognized assets (liabilities)$7.6 $(0.7)$3.9 $(0.2)
Gross amounts offset in the balance sheet— 0.1 (0.1)0.1 
Net amounts of assets (liabilities) presented in the balance sheet$7.6 $(0.6)$3.8 $(0.1)
(1)All derivative assets are presented in Other current assets or Other assets.
(2)All derivative liabilities are presented in Other current liabilities or Other liabilities.
18

Fair Value Hierarchy
Accounting guidance on fair value measurements for certain financial assets and liabilities requires that assets and liabilities carried at fair value be classified in one of the following three categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions or external inputs from inactive markets.
The following table sets forth the Company’s financial assets and liabilities, which are carried at fair value and measured on a recurring basis during the period, all of which are classified as Level 2 within the fair value hierarchy:
March 31,
2022		September 30,
2021
Liabilities at estimated fair value:  
Deferred compensation$(22.2)$(28.4)
Derivatives - foreign currency contracts7.0 3.7 
Net liabilities at estimated fair value$(15.2)$(24.7)
The estimated fair value of the deferred compensation liability is determined based upon the quoted market prices of the investment options that are offered under the plan. At March 31, 2022 and September 30, 2021, the estimated fair value of foreign currency contracts is the amount that the Company would receive or pay to terminate the contracts, considering first the quoted market prices of comparable agreements or, in the absence of quoted market prices, factors such as interest rates, currency exchange rates, and remaining maturities.
At March 31, 2022 and September 30, 2021, the Company had no Level 1 financial assets or liabilities, other than pension plan assets, and no Level 3 financial assets or liabilities at March 31, 2022 and at September 30, 2021.
At March 31, 2022 and September 30, 2021, the fair market value of fixed rate long-term debt was $1,157.3 and $1,300.1, respectively, compared to its carrying value of $1,250.0 in each period. The estimated fair value of the long-term debt was estimated using yields obtained from independent pricing sources for similar types of borrowing arrangements. The estimated fair value of long-term debt, excluding the U.S. revolving credit facility due 2025 (“Revolving Credit Facility”), has been determined based on Level 2 inputs.
Due to the nature of cash and cash equivalents and short-term borrowings, including notes payable, carrying amounts on the balance sheets approximate fair value. Additionally, the carrying amounts of the Revolving Credit Facility, which are classified as long-term debt on the balance sheet, approximate fair value due to the revolving nature of the balances. The estimated fair value of cash and cash equivalents, short-term borrowings, and the Revolving Credit Facility have been determined based on Level 2 inputs.

Note 15 - Segment Data
For an overview of the Company’s segments, refer to Note 1 to Notes to Condensed Consolidated Financial Statements.
Segment performance is evaluated based on segment profit, exclusive of general corporate expenses, share-based compensation costs, restructuring charges and certain costs deemed non-recurring in nature, including acquisition and integration costs, value-added tax (“VAT”) settlement costs, Sun Care reformulation costs, and the amortization of intangible assets. Financial items, such as interest income and expense, are managed on a global basis at the corporate level. The exclusion of such charges from segment results reflects management’s view on how it evaluates segment performance.
The Company’s operating model includes some shared business functions across the segments, including product warehousing and distribution, transaction processing functions and, in most cases, combined sales force and management teams. The Company applies a fully allocated cost basis in which shared business functions are allocated between the segments.
The Company completed the acquisition of Billie on November 29, 2021. Net Sales and Segment Profit associated with Billie products have been reported in the Wet Shave segment since the Acquisition Date. Fiscal 2022 acquisition and integration costs related to the Billie acquisition, while Fiscal 2021 costs related primarily to the Cremo acquisition, which was acquired on September 2, 2020.
19

Segment net sales and profitability are presented below:
 Three Months Ended
March 31,		Six Months Ended
March 31,
 2022202120222021
Net Sales 
Wet Shave$305.0 $292.7 $591.1 $571.8 
Sun and Skin Care183.3 159.5 288.1 262.5 
Feminine Care59.4 67.1 131.8 136.1 
Total net sales$547.7 $519.3 $1,011.0 $970.4 
Segment Profit 
Wet Shave$27.6 $45.9 $79.1 $98.5 
Sun and Skin Care42.3 36.2 46.0 41.4 
Feminine Care1.9 5.6 10.3 14.4 
Total segment profit71.8 87.7 135.4 154.3 
General corporate and other expenses(17.2)(13.4)(28.0)(25.5)
Restructuring and related costs(3.7)(5.5)(5.9)(9.9)
Acquisition and integration costs (1)
(1.1)(0.3)(7.1)(3.3)
VAT settlement costs (2)
— — (3.4)— 
Sun Care reformulation costs (3)
(0.2)— (3.5)— 
Amortization of intangibles(7.9)(5.6)(14.0)(11.1)
Cost of early retirement of long-term debt— (26.1)— (26.1)
Interest and other expense, net(14.6)(17.3)(30.2)(33.7)
Total earnings before income taxes$27.1 $19.5 $43.3 $44.7 
(1)Includes pre-tax SG&A of $0.6 and $6.3 for the three and six months ended March 31, 2022, respectively and $0.3 and $2.0 for the three and six months ended March 31, 2021, respectively. Additionally, includes Cost of products sold of $0.5 and $0.8 related to the valuation of acquired inventory for the Billie acquisition for the three and six months ended March 31, 2022, respectively. Cost of products sold includes $1.3 related to the valuation of acquired inventory for the Cremo acquisition for the six months ended March 31, 2021.
(2)Includes pre-tax SG&A of $3.4 for the six months ended March 31, 2022 related to the estimated settlement of prior years’ value-added tax audits in Germany.
(3)Includes pre-tax COGS of $0.2 and $3.5 for the three and six months ended March 31, 2022, respectively related to the recall and destruction of certain Sun Care products.
The following table presents the Company’s net sales by geographic area:
Three Months Ended
March 31,		Six Months Ended
March 31,
2022202120222021
Net Sales to Customers
United States$341.9 $301.8 $604.4 $552.7 
International205.8 217.5 406.6 417.7 
Total net sales$547.7 $519.3 $1,011.0 $970.4 

20

Supplemental product information is presented below for net sales:
Three Months Ended
March 31,		Six Months Ended
March 31,
 2022202120222021
Razors and blades$275.3 $262.4 $531.0 $508.7 
Tampons, pads, and liners59.4 67.1 131.8 136.1 
Sun care products131.4 103.0 171.6 131.8 
Grooming products34.4 33.1 80.7 76.2 
Wipes and other skin care17.5 23.4 35.8 54.5 
Shaving gels and creams29.7 30.3 60.1 63.1 
Total net sales$547.7 $519.3 $1,011.0 $970.4 

21

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
(Amounts in millions, except per share data, unaudited)
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited Condensed Consolidated Financial Statements and the accompanying notes included in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K filed with the SEC on November 19, 2021 (the “2021 Annual Report”). The following discussion may contain forward-looking statements that reflect our plans, estimates, and beliefs and involve risks, uncertainties, and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed within “Forward-Looking Statements” below and in Item 1A. Risk Factors and “Forward-Looking Statements” included within our 2021 Annual Report.
Forward-Looking Statements
This document contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of Edgewell Personal Care Company (“Edgewell,” “we” or “our Company”) or any of our businesses. Forward-looking statements generally can be identified by the use of words or phrases such as “believe,” “expect,” “expectation,” “anticipate,” “may,” “could,” “intend,” “belief,” “estimate,” “plan,” “target,” “predict,” “likely,” “will,” “should,” “forecast,” “outlook,” or other similar words or phrases. These statements are not based on historical facts, but instead reflect our expectations, estimates, or projections concerning future results or events, including, without limitation, the future earnings and performance of our Company or any of our businesses, and the integration of the Billie, Inc. (“Billie”) acquisition and expected benefits from this transaction, including growth opportunities and cost savings. Many factors outside our control could affect the realization of these estimates. These statements are not guarantees of performance and are inherently subject to known and unknown risks, uncertainties and assumptions that are difficult to predict and could cause our actual results to differ materially from those indicated by those statements. We cannot assure you that any of our expectations, estimates or projections will be achieved. The forward-looking statements included in this report are only made as of the date of this report and we disclaim any obligation to publicly update any forward-looking statement to reflect subsequent events or circumstances, except as required by law. You should not place undue reliance on these statements.
In addition, other risks and uncertainties not presently known to us or that we presently consider immaterial could significantly affect the forward-looking statements. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. Risks and uncertainties include those detailed from time to time in our publicly filed documents, including in Item 1A. Risk Factors of Part I of our 2021 Annual Report.
Non-GAAP Financial Measures
While we report financial results in accordance with GAAP, this discussion also includes non-GAAP measures. These non-GAAP measures are referred to as “adjusted” or “organic” and exclude items such as restructuring costs, acquisition and integration costs, and other non-standard items. Reconciliations of non-GAAP measures are included within this Management’s Discussion and Analysis of Financial Condition and Results of Operations.
This non-GAAP information is provided as a supplement to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. We use this non-GAAP information internally to make operating decisions and believe it is helpful to investors because it allows more meaningful period-to-period comparisons of ongoing operating results. Given certain significant events, including the acquisition of Billie, we view the use of non-GAAP measures that take into account the impact of these unique events as particularly valuable in understanding our underlying operational results and providing insights into future performance. The information can also be used to perform trend analysis and to better identify operating trends that may otherwise be masked or distorted by the types of items that are excluded. This non-GAAP information is also a component in determining management’s incentive compensation. Finally, we believe this information provides more transparency.
The following provides additional detail on our non-GAAP measures:
•We analyze net sales and segment profit on an organic basis to better measure the comparability of results between periods. Organic net sales and organic segment profit exclude the impact of changes in foreign currency and the impact of the Billie acquisition.
◦Organic net sales will be unfavorably impacted in fiscal 2022 by the Billie acquisition as sales that were previously reported as third party sales to Billie are now included as inter-company sales.
◦Segment profit will be unfavorably impacted in fiscal 2022 as a result of a change in the timing of profit recognition due to the Billie acquisition. Subsequent to the acquisition of Billie, profit previously earned on sales to Billie will be deferred until Billie sells to a third party.
22

•Additionally, we utilize “adjusted” non-GAAP measures including gross profit, SG&A, operating income, income taxes, net earnings, and diluted earnings per share internally to make operating decisions. The following items are excluded when analyzing non-GAAP measures: restructuring and related costs, acquisition and integration costs and other non-standard items.
All comparisons are with the same period in the prior year, unless otherwise noted.
Industry and Market Data
Unless we indicate otherwise, we base the information contained or incorporated by reference herein, concerning our industry on our general knowledge and expectations. Our market position, market share, and industry market size are estimates based on internal and external data from various industry analyses, our internal research and adjustments, and assumptions that we believe to be reasonable. We have not independently verified data from industry analyses and cannot guarantee its accuracy or completeness. In addition, we believe that industry, market size, market position and market share data within our industry provides general guidance but is inherently imprecise and has not been verified by any independent source. Further, our estimates and assumptions involve risks and uncertainties and are subject to change based on various factors, including those discussed in Item 1A. Risk Factors in Part I of our 2021 Annual Report. These and other factors could cause results to differ materially from those expressed in the estimates and assumptions. You are cautioned not to place undue reliance on this data.
Retail sales for purposes of market size, market position and market share information are based on retail sales in U.S. dollars.
Trademarks and Trade Names
We own or have rights to use trademarks and trade names that we use in conjunction with the operation of our business, which appear throughout this Quarterly Report on Form 10-Q. We may also refer to brand names, trademarks, service marks and trade names of other companies and organizations, which are the property of their respective owners.
Impact of COVID-19 Pandemic
Throughout the novel coronavirus 2019 (“COVID-19”) pandemic, we have taken and continue to take significant measures to protect our employees and businesses, while remaining in compliance with local and national guidelines.
The Company’s top priority during this time continues to be ensuring the health and welfare of our employees and additional health and safety measures have been put in place at all of our manufacturing locations. To date, we have not experienced a material operational disruption across our manufacturing or distribution facilities.
The prolonged COVID-19 pandemic environment has resulted in increased supply chain challenges across labor management, product procurement and distribution. The continued duration and severity of COVID-19 pandemic may cause further disruptions related to our key suppliers, increase procurement and distribution costs and impact our ability to hire and retain employees, which may result in higher labor costs going forward. However, the impact, timing and severity of potential disruptions cannot be reasonably estimated at this time.
We expect to maintain adequate liquidity, and we will continue to assess the impact that the COVID-19 pandemic has on our liquidity needs and current economic market conditions. As noted within “Liquidity and Capital Resources” below, the COVID-19 pandemic has not had a significant impact on our liquidity, cash flows or capital resources.

Significant Events
Acquisitions
On November 29, 2021, the Company completed the acquisition of Billie, a leading U.S. based consumer brand company that offers a broad portfolio of personal care products for women, for a purchase price of $309.4, net of cash acquired. We purchased Billie utilizing a combination of cash on hand and drawing on our U.S. revolving credit facility due 2025 (“Revolving Credit Facility”). As a result, Billie became a wholly owned subsidiary of the Company. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for further discussion.
23

Executive Summary
The following is a summary of key results for the second quarter and first six months of fiscal 2022 compared to the prior year period. Net earnings and earnings per share (“EPS”) for the periods presented were impacted by restructuring and related costs, acquisition and integration costs, and other non-standard items, as described in the table below. The impact of these items on reported net earnings and EPS are provided as a reconciliation of net earnings and EPS to adjusted net earnings and adjusted diluted EPS, both of which are non-GAAP measures.

Second Quarter of Fiscal 2022
•Net sales in the second quarter of fiscal 2022 increased 5.5% to $547.7. Organic net sales increased 2.1% compared to the prior year quarter due to strong Sun Care, Grooming and Women’s shave performance across both North American and International markets, partially offset by the impact of supply constraints on Feminine Care and certain Wet Shave brands and lower consumption in Wet Ones.
•Net earnings in the second quarter of fiscal 2022 were $23.2 compared to $14.4 in the prior year quarter. On an adjusted basis, net earnings for the second quarter of fiscal 2022 were $27.0 compared to $38.5 in the prior year quarter. Adjusted earnings declined compared to the prior year quarter as lower margins from inflationary pressures including higher materials, labor, and warehousing and distribution costs and higher advertising and promotional expense (“A&P”) were partially offset by higher net sales.
•Net earnings per diluted share during the second quarter of fiscal 2022 were $0.43 compared to $0.26 in the prior year quarter. On an adjusted basis, net earnings per diluted share during the second quarter of fiscal 2022 was $0.50 compared to $0.70 in the prior year quarter.
Three Months Ended March 31, 2022
Gross ProfitSG&AOperating Income
EBIT(1)
Income taxesNet EarningsDiluted EPS
GAAP — Reported$230.1$101.3$41.7 $27.1 $3.9 $23.2$0.43 
Restructuring and related costs—0.23.7 3.7 1.0 2.70.05 
Acquisition and integration costs0.50.61.1 1.1 0.2 0.90.02 
Sun Care reformulation costs0.2—0.2 0.2 — 0.2— 
Total Adjusted Non-GAAP$230.8$100.5$46.7 $32.1 $5.1 $27.0$0.50 
GAAP as a percent of net sales42.0 %18.5 %7.6 %GAAP effective tax rate14.4 %
Adjusted as a percent of net sales42.1 %18.3 %8.5 %Adjusted effective tax rate16.0 %
Three Months Ended March 31, 2021
Gross ProfitSG&AOperating Income
EBIT(1)
Income taxesNet EarningsDiluted EPS
GAAP — Reported$241.7 $93.4 $62.9 $19.5 $5.1 $14.4$0.26 
Restructuring and related costs— 2.8 5.5 5.5 1.3 4.20.08 
Acquisition and integration costs— 0.3 0.3 0.3 0.1 0.2— 
Cost of early debt retirement— — — 26.1 6.4 19.70.36 
Total Adjusted Non-GAAP$241.7$90.3$68.7 $51.4 $12.9 $38.5$0.70 
GAAP as a percent of net sales46.6 %18.0 %12.1 %GAAP effective tax rate26.6 %
Adjusted as a percent of net sales46.6 %17.4 %13.2 %Adjusted effective tax rate25.3 %
(1)EBIT is defined as Earnings before Income taxes.

First Six Months of Fiscal 2022
•Net sales for the first six months of fiscal 2022 increased 4.2% to $1,011.0. Organic net sales increased 2.3% compared to the prior year period, due to growth in Sun Care in globally, growth in Wet Shave in International markets and growth in Grooming in North America were offset, in part, by declines in Skin Care and Feminine Care.
24

•Net earnings for the first six months of fiscal 2022 were $34.4 compared to $32.1 in the prior year. On an adjusted basis, net earnings for the second quarter of fiscal 2022 were $50.2 compared to $61.8 in the prior year period. Adjusted earnings were down due to higher cost of goods sold from inflationary pressures, higher A&P and Selling, General and Administrative (“SG&A”) expense, largely related to amortization costs associated with the Billie acquisition.
•Net earnings per diluted share during the first six months of fiscal 2022 were $0.63 compared to $0.58 in the prior year period. On an adjusted basis, as illustrated in the following table, net earnings per diluted share during the first six months of fiscal 2021 were $0.92 compared to $1.13 in the prior year quarter.

Six Months Ended March 31, 2022
Gross ProfitSG&AOperating IncomeEBITIncome taxesNet EarningsDiluted EPS
GAAP — Reported$420.0 $198.2 $73.5 $43.3 $8.9 $34.4 $0.63 
Restructuring and related costs— 0.2 5.9 5.9 1.6 4.3 0.08 
Acquisition and integration costs0.8 6.3 7.1 7.1 0.5 6.6 0.12 
Value-added tax settlement costs— 3.4 3.4 3.4 1.1 2.3 0.04 
Sun Care reformulation costs3.5 — 3.5 3.5 0.9 2.6 0.05 
Total Adjusted Non-GAAP$424.3 $188.3 $93.4 $63.2 $13.0 $50.2 $0.92 
GAAP as a percent of net sales41.5 %19.6 %7.3 %GAAP effective tax rate20.5 %
Adjusted as a percent of net sales42.0 %18.6 %9.2 %Adjusted effective tax rate20.5 %

Six Months Ended March 31, 2021
Gross ProfitSG&AOperating IncomeEBITIncome taxesNet EarningsDiluted EPS
GAAP — Reported$435.0 $186.5 $104.5 $44.7 $12.6 $32.1 $0.58 
Restructuring and related costs0.1 3.4 9.9 9.9 2.5 7.4 0.14 
Acquisition and integration costs1.3 2.0 3.3 3.3 0.7 2.6 0.05 
Cost of early retirement of long-term debt— — — 26.1 6.4 19.7 0.36 
Total Adjusted Non-GAAP$436.4 $181.1 $117.7 $84.0 $22.2 $61.8 $1.13 
GAAP as a percent of net sales44.8 %19.2 %10.8 %GAAP effective tax rate28.4 %
Adjusted as a percent of net sales45.0 %18.7 %12.1 %Adjusted effective tax rate26.5 %
Operating Results
The following table presents changes in net sales for the second quarter and first six months of fiscal 2022, as compared to the corresponding period in fiscal 2021, and provides a reconciliation of organic net sales to reported amounts.

25

Net Sales
Net Sales - Total Company
Period Ended March 31, 2022
Q2% ChgSix Months% Chg
Net sales - fiscal 2021$519.3 $970.4 
Organic11.1 2.1 %22.4 2.3 %
Impact of Billie acquisition, net27.4 5.3 %34.2 3.5 %
Impact of currency(10.1)(1.9)%(16.0)(1.6)%
Net sales - fiscal 2022$547.7 5.5 %$1,011.0 4.2 %
For the second quarter of fiscal 2022, net sales were $547.7, an increase of 5.5%, including a $27.4 or 5.3% impact from the acquisition of Billie and a $10.1 or 1.9% unfavorable impact from currency movements. Organic net sales increased 2.1%, reflecting strong Sun Care, Grooming and Women’s shave performance across both North American and International markets, partially offset by the impact of supply constraints on Feminine Care and certain Wet Shave brands, and lower consumption in Wet Ones.
For the first six months of fiscal 2022, net sales were $1,011.0, an increase of 4.2%, including a $34.2 or 3.5% impact from the acquisition of Billie and a $16.0 or 1.6% unfavorable impact from currency movements. Organic net sales increased 2.3% driven by increased volumes in Sun Care and Grooming and favorable pricing for Feminine Care. The increases were offset by declines in volumes in Skin Care and Feminine Care.
For further discussion regarding net sales, including a summary of reported versus organic changes, see “Segment Results.”
Gross Profit
Gross profit was $230.1 during the second quarter of fiscal 2022, compared to $241.7 in the prior year quarter. Gross margin as a percent of net sales for the second quarter of fiscal 2022 was 42.0%. Adjusted gross margin percentage was 42.1%, a decline of 450-basis points compared to the prior year quarter, as 110-basis points of favorable pricing and 200-basis points of productivity gains were more than offset by a 560-basis point impact from commodity inflation and increased transportation and air-freight costs, a 140-basis point impact related to negative mix and higher non-trade spend, and a 60-basis point impact from Billie and unfavorable foreign exchange.
Gross profit was $420.0 during the first six months of fiscal 2022, compared to $435.0 in the prior year period. Gross margin as a percent of net sales for the first six months of fiscal 2022 was 41.5%. Adjusted gross margin percentage was 42.0%, down 300-basis points from the prior year period, driven by commodity inflation, higher warehousing and distribution expenses, and unfavorable product mix, which were partially offset by favorable pricing.
Selling, General and Administrative Expense
SG&A was $101.3 in the second quarter of fiscal 2022, or 18.5% of net sales, compared to $93.4 in the prior year quarter, or 18.0% of net sales. Adjusted SG&A as a percent of net sales was 18.3%, an increase of 90-basis points, driven by higher compensation expense and the additional costs associated with Billie, including increased amortization expense.
SG&A was $198.2 in the first six months of fiscal 2022, or 19.6% of net sales, compared to $186.5 in the prior year period, or 19.2% of net sales. Adjusted SG&A as a percent of net sales was 18.6%, a decline of 10-basis points, driven by lower broker and program expenses and leverage related to higher total net sales. The decline was offset by additional costs incurred associated with Billie, including amortization expense.
Advertising and Sales Promotion Expense
For the second quarter of fiscal 2022, A&P was $69.9, up $1.5 compared to the prior year quarter of $68.4. A&P as a percent of net sales was 12.8%, as compared to 13.2% in the prior year period. The increases in A&P expense were primarily driven by increases in support of sun season execution, the Schick Masterbrand launch and continued investments behind commercial activation in Japan and the U.K.
For the first six months of fiscal 2022, A&P was $116.1, up $6.5 compared to the prior year period. A&P as a percent of net sales was 11.5%, up from 11.3% in the prior year period. The increases in A&P expense were primarily driven by increases in support of Sun Care after COVID-19 pandemic declines in the prior year and higher investment in Wet Shave.
26

Research and Development Expense
Research and development expense (“R&D”) for the second quarter of fiscal 2022 was $13.7, compared to $14.3 in the prior year quarter. As a percent of net sales, R&D was 2.5% in the second quarter of fiscal 2022 compared to 2.8% in the prior year quarter. R&D for the first six months of fiscal 2022 was $26.5, compared to $28.0 in the prior year period. As a percent of net sales, R&D was 2.6% in the first six months of fiscal 2021, compared to 2.9% in the prior year period. R&D expense was down compared to the prior year driven primarily by timing of program spend for the first half of fiscal 2022.
Interest Expense Associated with Debt
Interest expense associated with debt for the second quarter of fiscal 2022 was $18.0, compared to $17.3 in the prior year quarter. For the first six months of fiscal 2022, interest expense was $35.3 compared to $34.7 in the prior year period. The increase in interest expense was the result of higher overall debt balance from the draw on the Revolving Credit Facility in the first quarter of fiscal 2022 primarily to finance the acquisition of Billie.
Other Income, net
Other income, net was $3.4 in the second quarter of fiscal 2022. There was no other income in the prior year quarter. Other income, net was $5.1 during the first six months of fiscal 2022, compared to $1.0 during the first six months of fiscal 2021. The increase in income was driven by favorable hedge settlements compared to the prior year.
Income Tax Provision
The effective tax rate for the three and six months ended March 31, 2022 was 14.4% and 20.5%, respectively, compared to 26.6% and 28.4% in the prior year period, respectively. On an adjusted basis, the effective tax rate was 16.0% and 20.5% for the three and six months ended March 31, 2022, respectively, and 25.3% and 26.5% for the three and six months ended March 31, 2021, respectively. The fiscal 2022 effective tax rate and adjusted effective tax rate reflect a favorable mix of earnings in low tax jurisdictions and a favorable impact of a change in our prior estimates.
Operating Model Redesign
In fiscal 2022, we expect to take specific actions to strengthen our operating model, simplify our organization and improve manufacturing and supply chain efficiency and productivity. As a result of these actions, we expect to incur one-time charges of approximately $15 in fiscal 2022. We incurred $3.7 and $5.9 during the second quarter and first six months of fiscal 2022, respectively, primarily related to employee severance and benefit costs.

Segment Results
The following tables present changes in segment net sales and segment profit for the second quarter and first six months of fiscal 2022, compared to the corresponding periods in fiscal 2021, and provide a reconciliation of organic segment net sales and organic segment profit to reported amounts. For a reconciliation of segment profit to Earnings before income taxes, refer to Note 15 of Notes to Condensed Consolidated Financial Statements.
Our operating model includes some shared business functions across segments, including product warehousing and distribution, transaction processing functions and, in most cases, a combined sales force and management teams. We apply a fully allocated cost basis in which shared business functions are allocated between segments.
Net sales and segment profit activity related to Billie products were included in the Wet Shave segment for the post-acquisition period.
Wet Shave
Net Sales - Wet Shave
Period Ended March 31, 2022
Q2% ChgSix Months% Chg
Net sales - fiscal 2021$292.7 $571.8 
Organic(6.1)(2.1)%(0.1)— %
Impact of Billie acquisition, net27.4 9.4 %34.2 6.0 %
Impact of currency(9.0)(3.1)%(14.8)(2.6)%
Net sales - fiscal 2022$305.0 4.2 %$591.1 3.4 %
Wet Shave net sales for the second quarter of fiscal 2022 increased 4.2% compared to the prior year quarter, inclusive of a 9.4% increase from the acquisition of Billie and a 3.1% decline due to currency movements. Organic net sales decreased $6.1, or 2.1%, driven by declines in Men’s systems primarily from lower volumes and unfavorable trade promotional spend in North America, which was partially offset by growth in Women’s systems in North America and International. Organic Net Sales in
27

North America were impacted by supply constraints which resulted in out-of-stocks for certain Women’s Systems and Men’s and Women’s Shave Preps.
Wet Shave net sales for the first six months of fiscal 2022 increased 3.4%, inclusive of a 6.0% increase from the acquisition of Billie and a 2.6% decline due to currency movements. Organic net sales were relatively flat compared to the prior year and were impacted by favorable pricing and volumes in Latin America, offset by unfavorable volumes due to supply chain constraints in North America. Geographically, International markets increased 2.6%, partially offset by declines in North America totaling 3.2%. There were increased volumes in Women’s Systems and Disposables, compared to declines in Men’s Systems and Shave preps.
Segment Profit - Wet Shave
Period Ended March 31, 2022
Q2% ChgSix Months% Chg
Segment profit - fiscal 2021$45.9 $98.5 
Organic(10.9)(23.7)%(7.7)(7.8)%
Impact of Billie acquisition, net(5.2)(11.3)%(7.6)(7.7)%
Impact of currency(2.2)(4.9)%(4.1)(4.2)%
Segment profit - fiscal 2022$27.6 (39.9)%$79.1 (19.7)%
Wet Shave segment profit for the second quarter of fiscal 2022 was $27.6, down $18.3, or 39.9%. Organic segment profit decreased $10.9, or 23.7%, as commodity inflation and increased transportation and air-freight costs were partially offset by favorable pricing across all markets.
Wet Shave segment profit for the first six months of fiscal 2022 was $79.1, down $19.4, or 19.7%. Organic segment profit decreased $7.7, or 7.8%, primarily due to inflationary pressures resulting in higher commodity costs and warehousing and distribution costs, partially offset by favorable pricing and lower A&P expense. Segment profit was negatively impacted $7.6 as a result of the Billie acquisition.
Sun and Skin Care
Net Sales - Sun and Skin Care
Period Ended March 31, 2022
Q2% ChgSix Months% Chg
Net sales - fiscal 2021$159.5 $262.5 
Organic24.8 15.5 %26.8 10.2 %
Impact of currency(1.0)(0.6)%(1.2)(0.4)%
Net sales - fiscal 2022$183.3 14.9 %$288.1 9.8 %
Sun and Skin Care net sales for the second quarter of fiscal 2022 increased 14.9%. Organic net sales increased $24.8, or 15.5%. The increase in organic net sales was primarily driven by Sun Care growth of more than 28%, reflecting distribution and market share gains in North America and continued category recovery in certain International markets. Additionally, Grooming grew 5.7%, primarily in North America. Wet Ones organic net sales declined 24.5%, reflecting the impact of cycling prior year quarter COVID-19 pandemic related heightened demand.
Sun and Skin Care net sales for the first six months of fiscal 2022 increased 9.8%. Organic net sales increased $26.8, or 10.2%. Organic net sales increases were driven by higher Sun Care volumes, resulting in growth of 31% globally, partially offset by unfavorable trade and coupons. Men’s Grooming increased 6% driven by Cremo and Jack Black. Wet Ones declined 34% driven by lower volumes as demand fell closer to pre-COVID-19 pandemic levels.
Segment Profit - Sun and Skin Care
Period Ended March 31, 2022
Q2% ChgSix Months% Chg
Segment profit - fiscal 2021$36.2 $41.4 
Organic6.0 16.6 %4.7 11.4 %
Impact of currency0.1 0.3 %(0.1)(0.3)%
Segment profit -fiscal 2022$42.3 16.9 %$46.0 11.1 %
28

Segment profit for the second quarter of fiscal 2022 was $42.3, an increase of $6.1. Organic segment profit increased $6.0, as higher sales in Sun Care were partially offset by inflationary cost pressures, higher A&P spend and sales declines in Wet Ones.
Segment profit for the first six months of fiscal 2022 was $46.0, an increase of $4.6, or 11.1%. Organic segment profit increased $4.7, or 11.4%, driven primarily by higher sales volumes, partially offset by higher A&P expense.
Feminine Care
Net Sales - Feminine Care
Period Ended March 31, 2022
Q2% ChgSix Months% Chg
Net sales - fiscal 2021$67.1 $136.1 
Organic(7.6)(11.4)%(4.3)(3.2)%
Impact of currency(0.1)(0.1)%— — %
Net sales - fiscal 2022$59.4 (11.5)%$131.8 (3.2)%
Feminine Care net sales for the second quarter of fiscal 2022 decreased $7.7, or 11.5%. The decline in net sales reflected the impact of supply constraints due to manufacturing labor shortages and certain ingredient shortages. Consumption increased driven by higher pricing, while market share increased slightly in the quarter.
Feminine Care net sales for the first six months of fiscal 2022 decreased $4.3, or 3.2%. Net sales declines were driven by lower volumes, partially offset by favorable pricing.
Segment Profit - Feminine Care
Period Ended March 31, 2022
Q2%ChgSix Months%Chg
Segment profit -fiscal 2021$5.6 $14.4 
Organic(3.7)(66.1)%(4.2)(29.2)%
Impact of currency— — %0.1 0.7 %
Segment profit - fiscal 2022$1.9 (66.1)%$10.3 (28.5)%
Feminine Care segment profit for the second quarter of fiscal 2022 was $1.9, a decrease of $3.7, or 66.1%, driven by the aforementioned supply chain constraints and increased transportation costs.
Feminine Care segment profit for the first six months of fiscal 2022 was $10.3 a decrease of $4.1, or 28.5%, primarily due to unfavorable gross margin from lower sales volumes and unfavorable cost mix due to inflationary pressures on materials, partially offset by favorable pricing.
General Corporate and Other Expenses
Quarter Ended March 31,Six Months Ended March 31,
2022202120222021
Corporate expenses$17.2 $13.4 $28.0 $25.5 
Restructuring and related costs3.7 5.5 5.9 9.9 
Acquisition and integration costs1.1 0.3 7.1 3.3 
Value-added tax settlement costs— — 3.4 — 
Sun Care reformulation costs0.2 — 3.5 — 
Cost of early retirement of long-term debt— 26.1 — 26.1 
General corporate and other expenses$22.2 $45.3 $47.9 $64.8 
% of net sales4.1 %8.7 %4.7 %6.7 %
For the second quarter of fiscal 2022, corporate expenses were $17.2, or 3.1% of net sales, compared to $13.4, or 2.6% of net sales. For the first six months of fiscal 2022, corporate expenses were $28.0, or 2.8% of net sales, compared to $25.5, or 2.6% of net sales. For the second quarter and six months ended March 31, 2022, the increase in corporate expense was primarily due to higher salary and benefit costs.
29

Liquidity and Capital Resources
At March 31, 2022, a portion of our cash balances were located outside the U.S. Given our extensive international operations, a significant portion of our cash is denominated in foreign currencies. We manage our worldwide cash requirements by reviewing available funds among the many subsidiaries through which we conduct business and the cost effectiveness with which those funds can be accessed. We generally repatriate a portion of current year earnings from select non-U.S. subsidiaries only if the economic cost of the repatriation is not considered material.
The counterparties that hold our deposits consist of major financial institutions. We consistently monitor positions with, and the credit ratings of, counterparties both internally and by using outside ratings agencies.
Our total borrowings were $1,454.8 at March 31, 2022, including $204.8 tied to variable interest rates. Our total borrowings at September 30, 2021 were $1,276.5. We had outstanding borrowings of $179.0 under the Revolving Credit Facility at March 31, 2022, primarily to fund the acquisition of Billie. Taking into account outstanding letters of credit of $6.3, as of March 31, 2022, $239.7 was available under the Revolving Credit Facility. We had outstanding international borrowings, recorded in Notes payable, of $25.8 and $26.5 as of March 31, 2022 and September 30, 2021, respectively.
Effective February 7, 2022, we increased the maximum receivables sold facility amount under the Sixth Amendment to Master Accounts Receivable Purchase Agreement to $180.0 from $150.0 and amended the pricing index used to determine the purchase price for subject receivables from LIBOR to the Bloomberg Short Term Bank Yield Index (“BSBY”). The applicable margin that is added to the BSBY pricing index specific for each obligor was unchanged. Except as noted above, all other terms, conditions, obligations, covenants or agreements contained in the Accounts Receivable Facility are unmodified in all respects and continue in full force and effect.
Historically, we have generated, and expect to continue to generate, positive cash flows from operations. Our cash flows are affected by the seasonality of our Sun Care products, typically resulting in higher net sales and increased cash generated in the second and third quarter of each fiscal year. While we cannot reasonably estimate the full impact of the COVID-19 pandemic will have on our cash flows, we believe our cash on hand, cash flows from operations and borrowing capacity under our Revolving Credit Facility will be sufficient to satisfy our future working capital requirements, interest payments, R&D activities, capital expenditures, and other financing requirements for at least the next 12 months. We will continue to monitor our cash flows, spending and liquidity needs.
To date, the COVID-19 pandemic has not had a significant impact on our liquidity or capital resources. However, the COVID-19 pandemic has led to disruption and volatility in the global capital markets, which, depending on future developments, could impact our capital resources and liquidity in the future.
Short-term financing needs consist primarily of working capital requirements and principal and interest payments on our long-term debt. Long-term financing needs will depend largely on potential growth opportunities, including acquisition activity and repayment or refinancing of our long-term debt obligations. We may, from time-to-time, seek to repurchase shares of our common stock. Such repurchases, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. Our long-term liquidity may be influenced by our ability to borrow additional funds, renegotiate existing debt, and raise equity on terms that are favorable to us.
As of March 31, 2022, we were in compliance with the provisions and covenants associated with our debt agreements.

30

Cash Flows
A summary of our cash flow activities is provided in the following table:
Six Months Ended March 31,
20222021
Net cash (used by) from:
Operating activities$(39.9)$(18.8)
Investing activities(325.7)(13.6)
Financing activities78.3 (52.1)
Effect of exchange rate changes on cash(3.8)1.9 
Net decrease in cash and cash equivalents$(291.1)$(82.6)
Operating Activities
Cash flow used by operating activities was $39.9 during the first six months of fiscal 2022, compared to $18.8 used during the prior year period, driven by lower adjusted net earnings.
Investing Activities
Cash flow used by investing activities was $325.7 during the first six months of fiscal 2022, compared to $13.6 used during the prior year period. We completed the acquisition of Billie for $309.4, net of cash acquired, in fiscal 2022. Additionally, we collected $5.0 of proceeds from the sale of the Infant and Pet Care business during the first six months of fiscal 2022, compared to $7.5 in the prior year period. Capital expenditures were $25.0 during the first six months of fiscal 2022, compared to $22.2 in the prior year period.
Financing Activities
Net cash from financing activities was $78.3 during the first six months of fiscal 2022, compared to cash used of $52.1 in the prior year period. During the first six months of fiscal 2022, we had net borrowings of $179.0 under our Revolving Credit Facility, primarily to fund the acquisition of Billie. We repurchased $75.4 of our common stock under our 2018 Board authorization to repurchase our common stock (the “Repurchase Plan”) compared to $9.2 in the prior year period. Dividend payments totaled $16.7 in the first six months of fiscal 2022, compared to $8.4 in the prior year period. We had financing outflows for employee equity awards held for taxes totaling $9.7 in the first six months of fiscal 2022, compared to $3.0 in the prior year period. In fiscal 2021, we replaced our $500 2022 Senior Notes with the issuance of $500 2029 Senior Notes. Additional financing cash outflows incurred were related to costs of early debt retirement of the 2022 Senior Notes totaling $26.5 and debt issuance costs of $5.9.

Share Repurchases
During the first six months of fiscal 2022, we repurchased 1.9 shares of our common stock for $75.4. We have 7.8 shares remaining under the Repurchase Plan. Future share repurchases, if any, would be made in the open market, privately negotiated transactions or otherwise, in such amounts and at such times as we deem appropriate based upon prevailing market conditions, business needs and other factors.

Dividends
On February 4, 2022, the Board declared a quarterly cash dividend of $0.15 per common share for the first fiscal quarter. The dividend was paid April 5, 2022, to stockholders of record as of the close of business on March 8, 2022.
Dividends declared during the six months ended March 31, 2022 totaled $16.6. Payments made for dividends during the six months ended March 31, 2022 totaled $16.7.
On May 6, 2022, the Board declared a quarterly cash dividend of $0.15 per common share for the second fiscal quarter. The dividend is payable July 7, 2022 to stockholders of record as of the close of business on June 2, 2022.

Commitments and Contingencies
Contractual Obligations
At March 31, 2022, we had outstanding borrowings of $179.0 under the Revolving Credit Facility. As of March 31, 2022, future minimum repayments of debt were: $179.0 in fiscal 2025, $750.0 in fiscal 2028 and $500.0 in fiscal 2029.
There have been no other material changes in our contractual obligations since the presentation in our 2021 Annual Report.
31

Item 3. Quantitative and Qualitative Disclosures About Market Risk.
The market risk inherent in our financial instruments and positions represents the potential loss arising from adverse changes in currency rates, commodity prices, and interest rates. At times, we enter into contractual arrangements (derivatives) to reduce these exposures. For further information on our foreign currency derivative instruments, refer to Note 14 of Notes to Condensed Consolidated Financial Statements. As of March 31, 2022, there were no open derivative or hedging instruments for future purchases of raw materials or commodities. Our exposure to interest rate risk relates primarily to our variable-rate debt instruments, which currently bear interest based on LIBOR plus margin. As of March 31, 2022, our outstanding variable-rate debt included $204.8 related to our Revolving Credit Facility and international, variable-rate notes payable. Assuming a one-percent increase in the applicable interest rates, annual interest expense on these variable-rate debt instruments would increase approximately $2.0.
There have been no material changes in our assessment of market risk sensitivity since our presentation of Quantitative and Qualitative Disclosures About Market Risk in our 2021 Annual Report on Form 10-K.

32

Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Exchange Act, is recorded, processed, summarized and reported within the specified time periods, and that such information is accumulated and communicated to management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosure.
Our management, with the participation of our CEO and CFO, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2022. Based on that evaluation, our CEO and CFO concluded that, as of that date, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended March 31, 2022 that have materially affected, or are likely to materially affect, our internal control over financial reporting.


33

PART II - OTHER INFORMATION
 
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
The following table sets forth the purchases of our Company’s securities by the Company and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) (17 CFR 240.10b-18(a)(3)) during the second quarter of fiscal 2022:
Period
 
Total Number of
 Shares Purchased (1) (2)

Average Price Paid
 per share (3)
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)
Maximum Number that May Yet Be Purchased Under the Plans or Programs
January 1 to 31, 2022119,931 $47.70 119,860 9,072,177 
February 1 to 28, 2022839,436 37.03 839,436 8,232,741 
March 1 to 31, 2022391,937 36.06 391,085 7,841,656 
(1)923 shares purchased during the quarter relate to the surrender to the Company of shares of common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock equivalent awards.
(2)In January 2018, our Board authorized a repurchase of up to 10 million shares of our Company’s common stock. This authorization replaced the prior share repurchase authorization of May 2015. During the second quarter of fiscal 2022, we repurchased 1,350,381 shares under this authorization.
(3)Includes $0.02 per share of brokerage fee commissions.
34

Item 6. Exhibits.
Exhibit NumberExhibit
3.1
3.2
3.3
10.1
10.2
10.3
10.4
31.1
31.2
32.1
32.2
101The following materials from the Edgewell Personal Care Company Quarterly Report on Form 10-Q formatted in inline eXtensible Business Reporting Language (“iXBRL”): (i) the Condensed Consolidated Statements of Earnings and Comprehensive Income for the three and six months ended March 31,2022 and 2021, (ii) the Condensed Consolidated Balance Sheets at March 31, 2022 and September 30, 2021, (iii) the Condensed Consolidated Statements of Cash Flows for the six months ended March 31, 2022 and 2021, (iv) the Condensed Consolidated Statements of Shareholder’s Equity for the three and six months ended March 31, 2022 and 2021 and (v) Notes to Condensed Consolidated Financial Statements. The financial information contained in the XBRL-related documents is “unaudited” and “unreviewed.”

35

SIGNATURES
 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 EDGEWELL PERSONAL CARE COMPANY
  
 Registrant
   
 By:/s/ Daniel J. Sullivan
  Daniel J. Sullivan
  Chief Financial Officer
  
  
Date:May 10, 2022  





36
Edgewell Personal Care (NYSE:EPC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Edgewell Personal Care Charts.
Edgewell Personal Care (NYSE:EPC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Edgewell Personal Care Charts.